Insilico Medicine to Present Three Abstracts on ISM5411 at 2026 Crohn’s & Colitis Congress

On January 22, 2026, Insilico Medicine announced three abstracts at the 2026 Crohn’s & Colitis Congress in Las Vegas on January 23, featuring clinical, preclinical safety, and efficacy data for ISM5411, a gut-restricted PHD1/2 inhibitor for IBD.12

Abstracts cover:
Phase 1 results in 76 healthy volunteers (no SAEs, low TEAEs at 25% vs 55% placebo, gut-restricted PK with low plasma exposure).2

13-week toxicology in two species (NOAEL 1000 mg/kg/day, ~100-fold higher colon vs plasma exposure).2

Efficacy in chronic T cell transfer colitis mouse model:
preventive/therapeutic dosing reduced disease severity, cytokines (IFN-γ, TNF-α, IL-6), inflammation, alone or with anti-TNF-α.2

ISM5411 stabilizes HIF-1α locally in the gut to promote mucosal protection and reduce inflammation with minimal systemic exposure.12

Sources:

1. https://bioquicknews.com/insilico-medicine-to-present-3-abstracts-at-2026-crohns-colitis-congress-highlighting-clinical-preclinical-safety-and-efficacy-data-for-ism5411-a-novel-gut-restricted-phd1-2-inhibito/

2. https://insilico.com/news/28ohjfj6u1-insilico-medicine-to-present-3-abstracts